NCT03532958View on ClinicalTrials.gov

Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Alopecia AreataAlopecia TotalisAlopecia Universalis
Interventions
DRUG

BNZ-1

PEGylated peptide inhibitor of IL-2, IL-9, and IL-15

DRUG

Normal saline

Dose volume consistent with weight-based dosing of BNZ-1

Sponsors

Lead Sponsor

Equillium
All Listed Sponsors
lead

Equillium

INDUSTRY

NCT03532958 - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | Biotech Hunter | Biotech Hunter